Dr. Andre Boulet reports

DEVONIAN HEALTH GROUP ANNOUNCES PUBLICATION OF LANDMARK STUDY HIGHLIGHTING THYKAMINE AS A PROMISING NEW ANTI-INFLAMMATORY AGENT

Devonian Health Group Inc. has published a peer-reviewed article in Biomedicines titled "Thykamine: A New Player in the Field of Anti-Inflammatory Drugs." The study presents notable evidence supporting the potent multitarget anti-inflammatory properties of Thykamine, the corporation's lead pharmaceutical candidate.

The article, published in the peer-reviewed BioMedicines journal and titled, "Thykamine: A New Player in the Field of Anti-Inflammatory Drugs," is now available on-line. It was co-written by Dr. Charles Lynde, associate professor in the department of medicine at the University of Toronto; Prof. Louis Flamand, department of microbiology, infectious disease and immunology, faculty of medicine, Universite Laval; Vincent McCarty; and Dr. John Sampalis, department of surgery, McGill University, Montreal, Canada.

In this study, researchers compared the effect of Thykamine with six widely prescribed anti-inflammatory drugs (including corticosteroids such as betamethasone, clobetasol, hydrocortisone and prednisone and non-steroidal therapies such as crisaborole and pimecrolimus). Using an in vitro model of immune-activated cells, they measured secretion levels of major chemokines (inflammatory markers) -- MCP-1, MIP-1alpha, MIP-1beta and RANTES (regulated on activation, normal T cell expressed and secreted) -- after inflammatory stimulation. Thykamine inhibited secretion of MCP-1, MIP-1alpha and MIP-1beta with significantly greater potency than all comparators and suppressed RANTES secretion to a degree comparable with or superior to most agents tested.

Importantly, these effects were observed at lower concentrations and without detectable cytotoxicity, suggesting a notably favourable safety profile. This unique combination of multitarget efficacy and cellular tolerability positions Thykamine as a strong candidate for next-generation therapeutic development targeting chronic inflammatory conditions.

A new paradigm for inflammation management

Chronic inflammation contributes to a wide spectrum of medical conditions, ranging from dermatological diseases such as atopic dermatitis (eczema) to gastrointestinal disorders and systemic autoimmune pathologies. When left unresolved, persistent inflammation can also drive the development of fibrosis-progressive tissue scarring that disrupts normal organ architecture and function. Over time, this fibrotic remodelling can lead to irreversible organ damage and failure, representing one of the most serious long-term consequences of chronic inflammatory diseases.

The findings published in Biomedicines reinforce Thykamine's potential to address this unmet medical need by offering a plant-derived, multimechanistic alternative capable of modulating inflammation across several biologically relevant pathways -- potentially impacting both inflammatory and fibrotic processes.

"The results with Thykamine are very encouraging. For too long, patients have had to choose between effectiveness and tolerability. Thykamine offers a real possibility of bridging that gap -- combining potent suppression of harmful inflammation with a gentler safety profile. We believe this could represent a paradigm shift in how we manage chronic inflammatory and autoimmune conditions," said Dr. Andre P. Boulet, PhD, chairman and chief executive officer of Devonian.

About Thykamine

Thykamine, the first pharmaceutical product issued from Devonian's Suprex platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a phase IIa clinical study in patients with mild to moderate distal ulcerative colitis and in a large phase II study in adult patients with mild to moderate atopic dermatitis. Both Thykamine and the Suprex platform are covered by patents issued in several North American, European and Asian countries.

About Devonian Health Group Inc.

Devonian is a clinical-stage pharmaceutical company specializing in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases, including, but not limited, to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favouring drug development pathway for prescription botanical drug products.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius, focused on selling prescription pharmaceutical products in Canada, under a licence from brand-name pharmaceutical companies.

Devonian Health Group was incorporated in 2015 and is headquartered in Quebec, Canada, where it owns a state-of-the-art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (symbol: GSD) and the OTCQB Venture Market (symbol: DVHGF).

We seek Safe Harbor.